Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Go back to Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer| (NASDAQ: ARVN) | Delayed: 7.58 -0.09 (1.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.67 | 52 Week High | $ | |||
| Open | $7.70 | 52 Week Low | $ | |||
| Day High | $7.76 | P/E | N/A | |||
| Day Low | $7.48 | EPS | $ | |||
| Volume | 309,340 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 25.07 -0.14 (0.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.21 | 52 Week High | $37.39 | |||
| Open | $25.22 | 52 Week Low | $28.25 | |||
| Day High | $25.31 | P/E | 15.19 | |||
| Day Low | $24.96 | EPS | $1.65 | |||
| Volume | 17,140,211 | |||||
